These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 11098533)

  • 1. [Therapeutic potential of thrombopoietin].
    Geissler K
    Wien Klin Wochenschr; 2000 Oct; 112(19):829-34. PubMed ID: 11098533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietins and thrombopoiesis: a clinical perspective.
    Kuter DJ
    Vox Sang; 1998; 74 Suppl 2():75-85. PubMed ID: 9704427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memorial lecture. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
    Hofmann WK; Ottmann OG; Hoelzer D
    Leukemia; 1999 Apr; 13 Suppl 1():S14-8. PubMed ID: 10232362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
    Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
    Hofmann WK; Ottmann OG; Hoelzer D
    Leukemia; 1999 Jan; 13(1):14-8. PubMed ID: 10049050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the potential for thrombopoietic agents in acute leukemia?
    Kuter DJ
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):553-8. PubMed ID: 22127320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effects of Mpl ligand administration and emerging clinical applications for the Mpl ligands.
    Kuter DJ
    Curr Opin Hematol; 1997 May; 4(3):163-70. PubMed ID: 9209831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.
    Kuter DJ; Begley CG
    Blood; 2002 Nov; 100(10):3457-69. PubMed ID: 12411315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Megakaryocyte growth and development factor (MGDF): an Mpl ligand and cytokine that regulates thrombopoiesis.
    Neumann TA; Foote M
    Cytokines Cell Mol Ther; 2000 Mar; 6(1):47-56. PubMed ID: 10976539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on thrombopoietin in preclinical and clinical trials.
    Miyazaki H
    Curr Opin Hematol; 1998 May; 5(3):197-202. PubMed ID: 9664160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin: biology and clinical potentials.
    Miyazaki H; Kato T
    Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression.
    Coleman D; Fairchild D; Schindler-Horvat J; Munyakazi L; Neumann TA
    Toxicol Sci; 1998 Sep; 45(1):77-87. PubMed ID: 9848114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
    Molineux G; Hartley C; McElroy P; McCrea C; McNiece IK
    Blood; 1996 Jul; 88(1):366-76. PubMed ID: 8704197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia.
    Vadhan-Raj S
    Semin Hematol; 2000 Apr; 37(2 Suppl 4):28-34. PubMed ID: 10831286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombocytopenia in HIV infection: impairment of platelet formation and loss correlates with increased c-Mpl and ligand thrombopoietin expression.
    Sundell IB; Koka PS
    Curr HIV Res; 2006 Jan; 4(1):107-16. PubMed ID: 16454716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
    Fanucchi M; Glaspy J; Crawford J; Garst J; Figlin R; Sheridan W; Menchaca D; Tomita D; Ozer H; Harker L
    N Engl J Med; 1997 Feb; 336(6):404-9. PubMed ID: 9010146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
    Basser RL; Underhill C; Davis I; Green MD; Cebon J; Zalcberg J; MacMillan J; Cohen B; Marty J; Fox RM; Begley CG
    J Clin Oncol; 2000 Aug; 18(15):2852-61. PubMed ID: 10920133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical use of thrombopoietin (c-Mpl Ligand)].
    Borota R; Borota J; Belić A; Gebauer E; Stefanović N
    Med Pregl; 1998; 51(11-12):501-8. PubMed ID: 10081270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
    Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
    Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.